CN110248948B - 墨蝶呤及其盐的多晶型物 - Google Patents

墨蝶呤及其盐的多晶型物 Download PDF

Info

Publication number
CN110248948B
CN110248948B CN201780084821.XA CN201780084821A CN110248948B CN 110248948 B CN110248948 B CN 110248948B CN 201780084821 A CN201780084821 A CN 201780084821A CN 110248948 B CN110248948 B CN 110248948B
Authority
CN
China
Prior art keywords
aminopterin
free base
crystalline
ray diffraction
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780084821.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN110248948A (zh
Inventor
D.E.莱维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ptc Medical Mp Co
PTC Therapeutics MP Inc
Original Assignee
Ptc Medical Mp Co
Censa Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Medical Mp Co, Censa Pharmaceuticals Inc filed Critical Ptc Medical Mp Co
Priority to CN202310843616.4A priority Critical patent/CN116903624A/zh
Publication of CN110248948A publication Critical patent/CN110248948A/zh
Application granted granted Critical
Publication of CN110248948B publication Critical patent/CN110248948B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201780084821.XA 2016-11-29 2017-11-28 墨蝶呤及其盐的多晶型物 Active CN110248948B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310843616.4A CN116903624A (zh) 2016-11-29 2017-11-28 墨蝶呤及其盐的多晶型物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662427686P 2016-11-29 2016-11-29
US62/427686 2016-11-29
US201762546390P 2017-08-16 2017-08-16
US62/546390 2017-08-16
PCT/US2017/063517 WO2018102315A1 (en) 2016-11-29 2017-11-28 Polymoprhs of sepiapterin and salts thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310843616.4A Division CN116903624A (zh) 2016-11-29 2017-11-28 墨蝶呤及其盐的多晶型物

Publications (2)

Publication Number Publication Date
CN110248948A CN110248948A (zh) 2019-09-17
CN110248948B true CN110248948B (zh) 2023-07-28

Family

ID=62241930

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310843616.4A Pending CN116903624A (zh) 2016-11-29 2017-11-28 墨蝶呤及其盐的多晶型物
CN201780084821.XA Active CN110248948B (zh) 2016-11-29 2017-11-28 墨蝶呤及其盐的多晶型物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202310843616.4A Pending CN116903624A (zh) 2016-11-29 2017-11-28 墨蝶呤及其盐的多晶型物

Country Status (14)

Country Link
US (4) US11072614B2 (enExample)
EP (1) EP3548497A4 (enExample)
JP (3) JP7148533B2 (enExample)
KR (3) KR102561697B1 (enExample)
CN (2) CN116903624A (enExample)
AU (3) AU2017366879C1 (enExample)
BR (1) BR122021026889A8 (enExample)
CA (1) CA3043502A1 (enExample)
CO (1) CO2019006018A2 (enExample)
IL (2) IL266955B2 (enExample)
MA (1) MA46973A (enExample)
MX (3) MX386520B (enExample)
NZ (1) NZ753504A (enExample)
WO (1) WO2018102315A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011132435A1 (ja) 2010-04-22 2011-10-27 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
NZ753504A (en) 2016-11-29 2025-10-31 Ptc Therapeutics Mp Inc Polymorphs of sepiapterin and salts thereof
CN111491635A (zh) * 2017-09-01 2020-08-04 显莎制药公司 包含墨蝶呤的药物组合物及其用途
EP3807279B1 (en) 2018-05-30 2025-12-31 PTC Therapeutics MP, Inc. Pharmaceutically acceptable sepiapterin salts with improved stability
JP7547215B2 (ja) 2018-05-30 2024-09-09 ピーティーシー セラピューティクス エムピー，インコーポレイテッド テトラヒドロビオプテリン血漿曝露を増加させるための組成物及び方法
US11617752B2 (en) 2018-05-30 2023-04-04 Ptc Therapeutics Mp, Inc. Methods for increasing sepiapterin plasma exposure
DK4009978T3 (da) 2019-08-05 2024-10-14 Ptc Therapeutics Mp Inc Anvendelse af Sepiapterin og metabolitter deraf for at behandle strålingseksponering
ES3041002T3 (en) 2019-09-25 2025-11-06 Ptc Therapeutics Mp Inc Methods for treating hyperphenylalaninemia
WO2021150983A1 (en) 2020-01-24 2021-07-29 Ptc Therapeutics Mp, Inc. Methods for treating parkinson's disease with sepiapterin
US20240122931A1 (en) 2021-02-09 2024-04-18 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin
AU2022221345A1 (en) 2021-02-09 2023-09-07 Ptc Therapeutics Mp, Inc. Methods for treating glioblastomas with sepiapterin
MX2024003909A (es) 2021-09-29 2024-06-28 Ptc Therapeutics Inc Composicion farmaceutica de sepiapterina.
WO2024249602A2 (en) * 2023-05-30 2024-12-05 The Board Of Trustees Of The Leland Stanford Junior University Restless leg syndrome (rls) and periodic leg movements (plms) during sleep: biomarker and drug target
CN117205164B (zh) * 2023-09-30 2024-07-26 山东新时代药业有限公司 一种盐酸沙丙蝶呤片剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104736539A (zh) * 2012-05-07 2015-06-24 白鸟制药株式会社 墨蝶呤和四氢乳酰蝶呤的制造法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
ES2177654T3 (es) 1994-08-05 2002-12-16 Suntory Ltd Remedio contra la degeneracion espinocerebelosa.
US5736343A (en) 1995-08-18 1998-04-07 Landry; Donald Detection of organic compounds through regulation of antibody-catalyzed reactions
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
BRPI0416105A (pt) 2003-10-31 2007-01-02 Altana Pharma Ag uso da bh4 para o tratamento de doença respiratórias
US7732599B2 (en) 2003-11-17 2010-06-08 Biomarin Pharmaceutical Inc. Process for preparing tetrahydrobiopterin and analogs of tetrahydrobiopterin
CN1894251B (zh) 2003-11-17 2011-06-29 默克和西伊公司 (6r)-l-赤型-四氢生物蝶呤二盐酸盐的晶型
PL1708690T3 (pl) 2003-11-17 2017-01-31 Biomarin Pharmaceutical Inc. Leczenie fenyloketonurii za pomocą BH4
CN101132776A (zh) 2004-11-17 2008-02-27 生物马林药物股份有限公司 稳定的四氢生物喋呤片剂制剂
JP2008523090A (ja) 2004-12-08 2008-07-03 バイオマリン ファーマシューティカル インコーポレイテッド 新生児肺高血圧症の治療のための方法および組成物
BRPI0609421B1 (pt) 2005-04-28 2021-06-01 Shiratori Pharmaceutical Co., Ltd. Processos para produção de um composto 1,1-bis-alquil sulfonila, para produção de um composto aldeído, e para produção de um derivado de hidrazona
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
ES2906582T3 (es) 2007-04-11 2022-04-19 Biomarin Pharm Inc Métodos para administrar tetrahidrobiopterina, composiciones asociadas y métodos de medida
CL2009000547A1 (es) 2008-03-10 2010-05-07 Takeda Pharmaceuticals Co Forma cristalina de (r)-2[[[3-metil-4-(2,2,2-trifluoroetoxi)-2-piridinil]metil]sulfinil]-1h-bencimidazol, metodo de preparacion; composicion farmaceutica y su uso para la profilaxis o tratamiento de ulcera peptica, gastritis, esofagitis erosiva, esofago de barret,dispepsia funcional, cancer gastrico.
US20110144117A1 (en) * 2008-08-12 2011-06-16 Orpha Swiss Gmbh Pharmaceutical Dosage Form Containing Tetrahydrobiopterin
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
WO2011132435A1 (ja) 2010-04-22 2011-10-27 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
CN103458900A (zh) 2011-03-01 2013-12-18 鲁必康研究私人有限公司 四氢生物蝶呤的稳定组合物
US9216178B2 (en) * 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
EP3468534A4 (en) 2016-06-13 2020-02-05 Meharry Medical College MODULATION OF THE NITRIC OXIDE SYNTHASE PATHWAY FOR ORAL HEALTH
WO2018019931A1 (en) 2016-07-29 2018-02-01 Dipharma S.A. Pharmaceutical composition kit comprising sapropterin dihydrochloride
TWI765936B (zh) 2016-11-29 2022-06-01 美商東京威力科創Ｆｓｉ股份有限公司 用以對處理腔室中之微電子基板進行處理的平移與旋轉夾頭
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
NZ753504A (en) 2016-11-29 2025-10-31 Ptc Therapeutics Mp Inc Polymorphs of sepiapterin and salts thereof
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
CN111491635A (zh) 2017-09-01 2020-08-04 显莎制药公司 包含墨蝶呤的药物组合物及其用途
EP3807279B1 (en) 2018-05-30 2025-12-31 PTC Therapeutics MP, Inc. Pharmaceutically acceptable sepiapterin salts with improved stability
JP7547215B2 (ja) 2018-05-30 2024-09-09 ピーティーシー セラピューティクス エムピー，インコーポレイテッド テトラヒドロビオプテリン血漿曝露を増加させるための組成物及び方法
US11617752B2 (en) 2018-05-30 2023-04-04 Ptc Therapeutics Mp, Inc. Methods for increasing sepiapterin plasma exposure
DK4009978T3 (da) 2019-08-05 2024-10-14 Ptc Therapeutics Mp Inc Anvendelse af Sepiapterin og metabolitter deraf for at behandle strålingseksponering
ES3041002T3 (en) 2019-09-25 2025-11-06 Ptc Therapeutics Mp Inc Methods for treating hyperphenylalaninemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104736539A (zh) * 2012-05-07 2015-06-24 白鸟制药株式会社 墨蝶呤和四氢乳酰蝶呤的制造法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Herstellung von (6R,S)-5,6,7,8-Tetrahydro-L-biopterin, 7,8-Dihydro-L-biopterin, L-Sepiapterin, Deoxysepiapterin, (6R,S)-5,6-Dihydrodeoxysepiapterin und 2’-Deoxybiopteri;BERNHARD SCHIRCKS，等;《HELVETICA CHIMICA ACTA》;19781231;第61卷(第7期);第2737页实施例5 *
WOLFGANG PFLEIDERER，等.Pteridine, LXVIII. Überführung von Biopterin in Sepiapterin und absolute Konfiguration des Sepiapterins.《CHEMISCHE BERICHTE》.1979,第112卷(第7期), *

Also Published As

Publication number Publication date
MA46973A (fr) 2019-10-09
CN110248948A (zh) 2019-09-17
AU2024200344B2 (en) 2025-11-06
KR20190086686A (ko) 2019-07-23
BR122021026889A2 (enExample) 2019-08-27
US20250230164A1 (en) 2025-07-17
WO2018102315A8 (en) 2018-09-07
AU2017366879B2 (en) 2022-02-24
US11773097B2 (en) 2023-10-03
US20190308975A1 (en) 2019-10-10
AU2017366879A1 (en) 2019-05-30
JP2019535836A (ja) 2019-12-12
JP2024123011A (ja) 2024-09-10
AU2022203481A1 (en) 2022-06-16
NZ753504A (en) 2025-10-31
US20210300930A1 (en) 2021-09-30
AU2024200344A1 (en) 2024-02-08
BR112019010222A2 (pt) 2019-08-27
IL266955B2 (en) 2023-09-01
EP3548497A4 (en) 2020-09-02
US20240043426A1 (en) 2024-02-08
AU2022203481B2 (en) 2023-10-19
CO2019006018A2 (es) 2019-06-19
MX386520B (es) 2025-03-19
EP3548497A1 (en) 2019-10-09
KR20250051124A (ko) 2025-04-16
IL301470A (en) 2023-05-01
MX2019006206A (es) 2019-08-14
BR112019010222A8 (pt) 2022-11-22
JP7148533B2 (ja) 2022-10-05
MX2021011676A (es) 2021-10-22
MX2021011683A (es) 2021-10-22
CN116903624A (zh) 2023-10-20
US12269829B2 (en) 2025-04-08
CA3043502A1 (en) 2018-06-07
AU2017366879C1 (en) 2022-08-11
IL266955A (en) 2019-07-31
KR102789662B1 (ko) 2025-04-03
BR122021026889A8 (pt) 2022-11-22
KR102561697B1 (ko) 2023-07-28
IL266955B1 (en) 2023-05-01
WO2018102315A1 (en) 2018-06-07
KR20230117467A (ko) 2023-08-08
JP2023002532A (ja) 2023-01-10
US11072614B2 (en) 2021-07-27

Similar Documents

Publication Publication Date Title
CN110248948B (zh) 墨蝶呤及其盐的多晶型物
US12325706B2 (en) Polymorphic form of sepiapterin
TW202118763A (zh) 可用於治療流感病毒感染之化合物
CN106255685B (zh) 用于预防或治疗疟疾的三氨基嘧啶化合物
NZ794827A (en) Polymorphs of sepiapterin and salts thereof
RU2851633C1 (ru) Соединения хиназолина, содержащие спиро-кольцо
BR122025000511A2 (pt) Forma cristalina de base livre de sepiapterina, composição farmacêutica que a compreende, uso da mesma e método de preparação de uma formulação líquida
BR122025000503A2 (pt) Forma cristalina de base livre de sepiapterina, composição farmacêutica que a compreende, uso da mesma e método de preparação de uma formulação líquida
BR112019010222B1 (pt) Formas d e f cristalinas de base livre de sepiapterina, suas composições, usos e método de preparação de uma formulação líquida compreendendo as mesmas

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Massachusetts, USA

Applicant after: CENSA PHARMACEUTICALS Inc.

Address before: Washington State

Applicant before: CENSA PHARMACEUTICALS Inc.

CB02 Change of applicant information

Address after: New jersey, USA

Applicant after: PTC THERAPEUTICS, Inc.

Address before: Massachusetts, USA

Applicant before: CENSA PHARMACEUTICALS Inc.

CB02 Change of applicant information
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Massachusetts, USA

Applicant after: PTC medical MP Co.

Address before: New jersey, USA

Applicant before: PTC THERAPEUTICS, Inc.

CB02 Change of applicant information
CB02 Change of applicant information

Address after: New jersey, USA

Applicant after: PTC medical MP Co.

Address before: Massachusetts, USA

Applicant before: PTC medical MP Co.

GR01 Patent grant
GR01 Patent grant